Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic.
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Nonalcoholic steatohepatitis (NASH) reflects severe liver disease within the NAFLD spectrum and can progress to end-stage liver disease. Within this manuscript we review the available evidence for the treatment of NASH as well as the newer therapeutic agents that are currently being investigated.
Department of Pediatrics, Division of Gastroenterology, Hospital for Sick Children (Marialena Mouzaki) ; Department of Medicine, University Health Network (Marialena Mouzaki, Johane Allard), Toronto, ON, Canada.
Marialena
M
Mouzaki
Department of Medicine, University Health Network (Marialena Mouzaki, Johane Allard), Toronto, ON, Canada.
Johane
J
Allard
NASH; fatty liver; pioglitazone; treatment; vitamin E